Drug Profile
Research programme: TRPV1 antagonists - Eli Lilly and Company
Alternative Names: Transient receptor potential vanilloid subtype-1 antagonists - Eli Lilly and Company; VR1 antagonists - Eli Lilly and CompanyLatest Information Update: 24 Mar 2009
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class
- Mechanism of Action TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Pain; Urinary incontinence
Most Recent Events
- 30 Oct 2007 Preclinical trials in Inflammation in USA (unspecified route)
- 30 Oct 2007 Preclinical trials in Pain in USA (unspecified route)
- 30 Oct 2007 Preclinical trials in Urinary incontinence in USA (unspecified route)